Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Biogen Investigational Drug Shows Early Promise


 
Photo from the Sept. 1 issue of Nature courtesy of Biogen and the study authors.

Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, published in the Sept. 1, 2016 issue of Nature.

Information released by Biogen said the pre-clinical animal model and Phase 1b placebo-controlled study in prodromal and mild AD patients (n=165), both demonstrated aducanumab reduced amyloid-beta in the brain and that the reduction was dose-dependent. With the association of amyloid plaque and AD, the hypothesis is that removing the plaque could slow the clinical decline in AD patients. Exploratory results from the Phase 1b study demonstrated dose- and time-dependent slowing of clinical decline as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and the Mini-Mental State Examination (MMSE) scores.

"These early studies of aducanumab show its effectiveness in removing amyloid plaque from the brain, as well as its potential effect on the slowing of cognitive decline in patients suffering from Alzheimer's disease," said Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen.

Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune's technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

In the Phase 1b study, aducanumab demonstrated acceptable safety and tolerability profiles. The most frequently reported treatment-related serious adverse event and adverse event was ARIA (amyloid-related imaging abnormalities). Two larger Phase 3 trials are currently underway.

 
Share:

Related Articles:


Recent Articles

Integrating AI in Healthcare

Technology has advanced to a point where AI in healthcare is increasingly common. Now the challenge is utilizing data in a way that is not only predictive but also prescriptive to improve health and outcomes.

Read More

AMA Advances New Principles to Put AI into Practice

AHIP isn't the only national organization focused on how AI might be effectively deployed to improve patient engagement, care and interaction with the broader healthcare system.

Read More

State of Technology

Nashville HIT leaders address challenges, accomplishments of the region's thriving healthcare IT market.

Read More

Helping Children and Athletes Breathe Easier

Experiencing shortness of breath during exercise can be extremely distressing, particularly when it occurs in a child, teen or young adult.

Read More

PHYSICIAN SPOTLIGHT: Between Medicine and Technology

When it comes to rolling out new systems, Neal Patel, MD, said listening to users and understanding concerns are critical to success.

Read More

Navigating the Risks of New Healthcare Technologies

New technologies in healthcare hold great promise, but with that promise come risks that must be considered and addressed.

Read More

Tech Talk

Recent news of note in Middle Tennessee's health tech sector.

Read More

Enhancing Access to Care through Technology

Innovative technology allows patients, health plans to schedule appointments online.

Read More

Reimaging Residency

A joint project between Vanderbilt and Ole Miss was one of eight selected by the American Medical Association to reimagine residency programming.

Read More

Tips & Traps: Expert Insights from NMGMA Leadership

NMGMA's president and president-elect share insights borne of experience to help practice managers enhance success.

Read More

Email Print
 
 

 

 


Tags:
Aducanumab, Alfred Sandrock, Alzheimer's, Alzheimer's Disease Neuroimaging Initiative, Amyloid Plaque, Biogen, Cognitive Decline
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: